MC2VR01 Micra VR2
Transcatheter Pacing System (TPS)
MC2VR01 Micra VR2
Information

Device Survival Probability

MC2VR01_SURV
Loading...










    1 yr at 14.0 mo                
% Excluding Normal Battery Depletion 100.0 100.0                
% Including Normal Battery Depletion 99.8 99.8                
#   290 115                
  • Including Normal Battery Depletion – This curve includes devices that have reached at least 80% of expected longevity. This curve is most representative of clinical performance and how long the device will last.
  • Excluding Normal Battery Depletion – This is the malfunction free survival curve.
Information

Customer Communications For This Model

Information

Product Characteristics

Generator Type TPS
NBD Code VVIR
Max. Delivered Energy N/A
More
Serial Number Prefix MVR
Mass 1.75 g
Volume 1 cc
Waveform N/A
X-Ray ID Medtronic Logo
Hide this content
Information

CareLink Population

Enrolled 2992
Active 2879
Cumulative Follow-Up Months 17451
Normal Battery Depletion 2
Information 0

CareLink Qualifying Malfunctions/Complications

Information

Distribution Data

US Market Release2023-04-20
CE Approval Date2024-01-04
Registered USA Implants6428
US Market Release2023-04-20
CE Approval Date2024-01-04
Estimated WW Distribution10454
Information

*Acute Observations (N = 6428)

Dislodgement3
Elevated Pacing Threshold14
Failure to Capture8
Failure to Sense5
Information

*Day of Implant Observations (N = 6428)

Cardiac Perforation7
Dislodgement10
Elevated Pacing Threshold20
Failure to Capture13
Failure to Sense4

The rate of perforation for commercially released Micra devices continues to perform acceptably within levels observed within the post-approval clinical study registry. Overall, predicate clinical studies for Micra VR have demonstrated a reduction in the risk of major complications of 63% through 12 months1 and 57% through 36 months2 relative to transvenous pacing systems.

Information

EOS Indicator

From the point that the RRT is set, the pacemaker will operate for approximately six months for typical pacemaker configurations during the normal operating life.

Information

Recommended Replacement (RRT)

6 months before battery voltage measures less than or equal to 2.5V on 3 consecutive daily automatic measurements.

Information

Estimated Longevity

Amplitude Setting 500 Lead Ω 700 Lead Ω
Low 1.0 V 16.3 17.4
Nominal 2.0 V 10.2 11.8
High 2.5 V 7.8 9.4
Footnote

Longevity estimates based on the following device usage. Pace/Sense Mode VVI Right Ventricle Pulse Width 0.24 ms; Lower Pace Rate 60 bpm; Right Ventricle Percent Paced 100 %; VCM Mode: Adaptive, 0.5 VHide this content

1. El-Chami et al. Heart Rhythm 2018 15(12): 1800-1807.
2. Piccini et al. Heart Rhythm 2020 17(5 Supplement) D-PO02-089
* Data in these tables is sourced direct from the MDT complaint handling database summarizing observations reported to Medtronic relative to the registered US implant population.

Data as of November 20, 2024

www.medtronic.com/productperformance 1026050